The Growing Global Threat Of Antibiotic Resistance Ielts Reading Answers Online
Typical for this passage:
| Question Type | Example Task | |---------------|----------------| | True / False / Not Given | "Antibiotic resistance only affects low-income countries." | | Matching Headings | Match paragraph titles like "The Agricultural Link" to sections | | Summary Completion (with word bank) | Fill gaps: "Overuse of antibiotics in ___ has accelerated resistance." | | Matching Features | Match researchers/organizations (WHO, O’Neill, CDC) to their findings | | Multiple Choice | What is the main reason resistance spreads globally? | | Sentence Completion | "Without action, deaths from AMR could reach ___ per year by 2050." |
For much of human history, common infections were a death sentence. The discovery of penicillin by Alexander Fleming in 1928 heralded the golden age of antibiotics, transforming medicine and saving hundreds of millions of lives. However, in recent decades, this medical miracle has been steadily eroding. The rise of antimicrobial resistance (AMR) – specifically antibiotic resistance – is now recognised by the World Health Organization (WHO) as one of the top ten global public health threats facing humanity. Without urgent action, the world is heading towards a ‘post-antibiotic’ era, where minor injuries and routine operations could once again become fatal. Researchers warn that if current trends continue, drug-resistant infections could kill 10 million people per year by 2050, surpassing cancer as a leading cause of death. Typical for this passage: | Question Type |
Reading Passage
Antibiotics have been hailed as one of the greatest medical breakthroughs of the 20th century. Since the discovery of penicillin by Alexander Fleming in 1928, these ‘miracle drugs’ have saved millions of lives by combating bacterial infections that were once fatal. However, in recent decades, the efficacy of these drugs has been steadily eroding. The rise of antimicrobial resistance (AMR) – specifically antibiotic resistance – is now recognised by the World Health Organization (WHO) as one of the top ten global public health threats facing humanity. However, in recent decades, this medical miracle has
Antibiotic resistance occurs when bacteria evolve mechanisms to withstand the drugs designed to kill them. This is a natural evolutionary process, but it has been dramatically accelerated by human actions. When a person takes antibiotics, sensitive bacteria are killed, but resistant strains may survive and multiply. These resistant bacteria can then spread to other people, animals, and the environment. The core problem, experts argue, is the overuse and misuse of these vital medicines.
One of the primary drivers of resistance is the unnecessary prescription of antibiotics for viral infections, such as the common cold or flu, against which they are entirely ineffective. In many countries, antibiotics are also readily available without a prescription, leading to inappropriate self-medication. Furthermore, the agricultural sector is a significant contributor. In many parts of the world, large quantities of antibiotics are used not only to treat sick livestock but also to promote growth and prevent disease in healthy animals. This practice creates a reservoir of resistant bacteria that can transfer to humans through the food chain and direct contact. Without a united
The consequences of unchecked resistance are catastrophic. Common medical procedures that rely on preventative antibiotics – such as caesarean sections, hip replacements, and chemotherapy – could become too risky to perform. Simple infections from a scratch or a routine operation could once again become fatal. The WHO estimates that at least 700,000 people die each year from drug-resistant infections. If no action is taken, this figure is projected to reach 10 million per year by 2050, surpassing cancer as a leading cause of death.
Compounding this crisis is the lack of new drug development. Creating a new antibiotic is scientifically challenging, costly (over $1 billion), and commercially unattractive. Pharmaceutical companies have little financial incentive because new antibiotics are typically reserved for emergency use to prevent resistance from developing, ensuring low sales volumes. Consequently, the pipeline for new antibiotics has run dry; no truly novel class of antibiotics has been discovered since the 1980s.
To address this threat, a coordinated global response is required. The WHO’s Global Action Plan on AMR outlines five key objectives: to improve awareness and understanding of AMR, to strengthen surveillance and research, to reduce the incidence of infection through hygiene and vaccination, to optimise the use of antimicrobials in humans and animals, and to develop the economic case for sustainable investment in new medicines. Some countries have already taken action. For instance, Sweden has successfully reduced antibiotic use in its animal population through strict regulations, and the UK has introduced a ‘subscription’ model to pay pharmaceutical companies for access to new antibiotics, regardless of how many are sold.
Nevertheless, progress remains uneven. Low- and middle-income countries often lack the regulatory infrastructure and public health systems needed to enforce controls on antibiotic sales and monitor resistance patterns. Without a united, global effort that includes governments, the pharmaceutical industry, healthcare providers, and individual patients, the post-antibiotic era – a time when minor infections could kill – will become a reality.